

SUBACUTE LOW DOSE NERVE AGENT EXPOSURE CAUSES DNA FRAGMENTATION IN GUINEA PIG LEUKOCYTES.

Jitendra R. Dave¹, John R. Moffett¹, Sally M. Anderson¹, Rebecca A. Price¹, Rebecca Whipple¹, Maurice L. Sipos², Anita V. Moran², Suzanne M. DeFord², and Frank C. Tortella¹.

¹Division of Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD, USA 20910 and ²U.S. Army Research Institute of Chemical Defense, Drug Assessment Division/Advanced Assessment Branch, Aberdeen Proving Ground, MD, USA 21010.

ABSTRACT

The objective of present study was to determine levels of DNA fragmentation in blood leukocytes from guinea pigs by ‘Comet’ assay after exposure to soman at doses ranging from 0.1LD₅₀ to 0.4 LD₅₀, once per day for 10 days. Post-exposure recovery periods were 0, 17 or 110 days. Leukocytes were imaged from each animal, and the images analyzed by computer. Data obtained for exposure to soman demonstrated significant increases in DNA fragmentation in circulating leukocytes in CWNA treated guinea pigs as compared with saline injected control animals at all doses at 0 and 17 days post-exposure periods. Notably, significantly increased DNA fragmentation was observed in leukocytes 17 days after cessation of soman exposure. However, no significant DNA fragmentation was observed at 110 days post-exposure. Our findings demonstrate that leukocyte DNA fragmentation assays may provide a sensitive biomarker for low dose CWNA exposure.

INTRODUCTION

The possible involvement of chemical warfare nerve agents (CWNA) in the etiology of “Gulf War Syndrome” among armed forces personnel deployed to the Persian Gulf in 1990 has been a controversial issue [1]. Despite the fact that US military surveillance teams detected no exposures to chemical weapons, other countries claim to have detected low-level gaseous nerve agents (Persian Gulf War Veterans Coordinating Board 1995 [2]). These facts and other chemical terrorist attacks pose a definite threat to both civilians and military personnel in the US and overseas, and as such, research into methods of protecting against nerve-agent induced tissue and brain injury has become of prime importance.

Nerve agents, such as soman, sarin and tabun are extremely toxic, irreversible cholinesterase inhibitors that can be used in military operations, or by terrorists, to kill,

Report Documentation Page

*Form Approved
OMB No. 0704-0188*

Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

| | | | | | |
|--|------------------------------------|--|----------------------------|---------------------|---------------------------------|
| 1. REPORT DATE 01 OCT 2005 | 2. REPORT TYPE N/A | 3. DATES COVERED - | | | |
| 4. TITLE AND SUBTITLE Subacute Low Dose Nerve Agent Exposure Causes Dna Fragmentation In Guinea Pig Leukocytes | | 5a. CONTRACT NUMBER | | | |
| | | 5b. GRANT NUMBER | | | |
| | | 5c. PROGRAM ELEMENT NUMBER | | | |
| 6. AUTHOR(S) | | 5d. PROJECT NUMBER | | | |
| | | 5e. TASK NUMBER | | | |
| | | 5f. WORK UNIT NUMBER | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Division of Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD, USA 20910 | | 8. PERFORMING ORGANIZATION REPORT NUMBER | | | |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) | | 10. SPONSOR/MONITOR'S ACRONYM(S) | | | |
| | | 11. SPONSOR/MONITOR'S REPORT NUMBER(S) | | | |
| 12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited | | | | | |
| 13. SUPPLEMENTARY NOTES See also ADM001851, Proceedings of the 2003 Joint Service Scientific Conference on Chemical & Biological Defense Research, 17-20 November 2003. , The original document contains color images. | | | | | |
| 14. ABSTRACT | | | | | |
| 15. SUBJECT TERMS | | | | | |
| 16. SECURITY CLASSIFICATION OF: | | | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES | 19a. NAME OF RESPONSIBLE PERSON |
| a. REPORT unclassified | b. ABSTRACT unclassified | c. THIS PAGE unclassified | UU | 7 | |

incapacitate, or seriously injure innocent people. These organophosphates exert their effects by inactivating the enzyme acetylcholinesterase, and causing accumulation of acetylcholine at neuronal synapses and at neuromuscular junctions, resulting in hyperactivity of the cholinergic system, and tetany of skeletal muscles, including the diaphragm [3]. Anticholinergic compounds have been demonstrated to provide variable degrees of neuroprotection against organophosphates [4]. Recent studies have also attributed involvement of NMDA receptor modulation, in conjunction with the anticholinergic properties of neuroprotective drugs like caramiphen, against organophosphate toxicity [5].

Neuronal DNA fragmentation in response to CNS injury is a well-studied phenomenon, however, leukocyte DNA fragmentation in response to injury is less well studied. Similarly, although cellular DNA fragmentation or apoptosis is a well-documented process following traumatic or ischemic injury, its involvement in nerve agent-induced cellular degeneration remains to be elucidated. In particular, it is not known what effects low-level nerve agent exposure might have on leukocyte function and integrity. In this report, we quantify the level of DNA fragmentation in circulating leukocytes associated with low dose soman-mediated injury using the single cell electrophoresis “comet” assay to determine if such assays could be used as a biomarker for low dose CWNA exposure.

Materials and methods

Male Guinea pigs (400 – 500gm, n = 3 to 4 per group, total = 47) were injected with saline, or 0.1 LD₅₀, 0.2 LD₅₀, or 0.4LD₅₀ soman (1ml/kg) dissolved in sterile physiological saline, Monday through Friday, once a day at 0800 hours for 10 days (animals were not injected on the weekend). At 1200 hours on day 10, day 29 or day 122, animals were anesthetized with pentobarbital (325 mg/kg) and sacrificed by decapitation. Blood was collected in tubes containing EDTA, and kept on ice until processed for comet analysis.

Whole blood (100 µl) from each animal was added to 1 ml of ice cold Ca⁺⁺ Mg⁺⁺ free PBS with 20mM EDTA. The mixtures were centrifuged at 1000 x g for 10 min to remove plasma, and the cell pellet was re-suspended in 1 ml of the same solution. Cells were washed by this method 2 more times to remove cell debris. The final pellet was suspended in 1 ml of ice cold PBS with 20mM EDTA, and 50µl was removed and combined with 500 µl of low melting point agarose (LMAgarose: Trevigen, Gaithersburg MD) warmed to 42°C. For rest of the procedure the manufacturer’s (Trevigen, Gaithersburg, MD) protocol was used for comet assay. Briefly, a 50 µl aliquot of this mixture was transferred to specially treated slides and allowed to cool. Slides were then immersed in ice-cold lysis solution (pH 9.6; Trevigen) and incubated for 30 minutes at 4°C. Slides were then moved to an alkali buffer solution (0.6 g NaOH and 100 µl 0.5 M EDTA in 50 ml of purified water, pH 12.8) for 20 to 30 minutes at room temperature. Slides were then washed twice in Tris-borate EDTA solution (TBE buffer, pH 8.4), 5 minutes each, and then placed in the electrophoresis chamber. Electrophoresis was run for 10 minutes at 25mV in TBE buffer. Slides were removed from the apparatus and were fixed for 5 minutes with ice cold 100% MeOH, followed by 5 minutes in ethanol, and then were dried in the dark at room temperature.

For quantification of DNA fragmentation, 30 leukocytes were imaged per animal, with 3 to 4 animals in each group (90 to 120 individual leukocytes per group). Specially designed comet analysis software (Loats Associates, Westminster MD) was used to analyze the degree of DNA fragmentation in individual leukocytes. Slides were covered with 50 μ l of 0.01% SYBR Green (Trevigen) in Tris-EDTA buffer and imaged with a monochrome digital camera connected to an Olympus BX60 fluorescent microscope using a 20X objective.

The comet assay does not provide a measure of the number of cells that are apoptotic out of the population of imaged leukocytes. Therefore, a direct count of apoptotic cells was undertaken. For each animal, 500 cells were counted, and the percentage that was clearly apoptotic was tabulated. Leukocytes were not scored as apoptotic unless there was a clear comet head and comet tail, as well as granularity of the fluorescent signal in the nucleus.

Results

Figure 1 presents the data obtained from counting over 32,000 cells from the 66 animals in the current study. Leukocytes with DNA fragmentation were rare in blood samples from the saline-injected animals, but were significantly more numerous in blood from soman-injected animals. Typically, normal leukocytes had smooth edges, and little or no DNA was observed in the comet tail. When DNA fragmentation was present, the fluorescent signal in the nucleus appeared granular, the edges of the nucleus were uneven, and some of the DNA had migrated out of the nucleus into the comet tail (a hallmark of apoptosis). As seen in figure 1, a dose response was observed for all three groups of animals in the study, where increasing soman exposure from 0.1LD₅₀ to 0.4LD₅₀ resulted in an increase in DNA fragmentation. The maximal effect was observed in the 0.4LD₅₀ group with 10-days of soman exposure, followed by 17 days of recovery, where over 17% of leukocytes had DNA fragmentation, as compared with just over 6% for the saline control group. These values of % apoptotic leukocytes returned to control levels after 10-days of soman exposure, followed by 110 days of recovery.




Figure 1: Percent of leukocytes exhibiting apoptosis after soman exposure at four doses and three time points. Three to four guinea pigs were in each group, and 250 to 500

leukocytes were counted per animal. Only cells that exhibited a clear comet head and tail, as well as nuclear granularity, were counted as apoptotic. Error bars represent the standard error of the mean (n=3 to 4 animals per group).

DNA fragmentation in circulating leukocytes was significantly increased in blood samples from all soman-treated animals, at all time points, as shown in Tables 1-3. Table 1 shows several measures of DNA fragmentation in leukocytes collected from guinea pigs injected with soman for 10 days. The average comet tail moment arm increased from 11.95 ± 0.83 for the control group to 18.18 ± 0.43 in the $0.1LD_{50}$ group, to 21.04 ± 1.26 in the $0.2LD_{50}$ group, to 22.38 ± 1.39 for the $0.4LD_{50}$ group. The average percentage DNA in the comet tails increased from 1.26 ± 0.10 in the control animals to 3.48 ± 0.35 in the $0.1LD_{50}$ group, to 3.00 ± 0.37 in the $0.2LD_{50}$ group, to 3.96 ± 0.41 in the $0.4LD_{50}$ group. The average comet tail length increased from 28.02 ± 1.90 in the control group to 45.03 ± 1.12 in the $0.1LD_{50}$ group, to 49.76 ± 2.74 in the $0.2LD_{50}$ group, to 53.08 ± 3.16 in the $0.4LD_{50}$ group.

Table 1: Comet parameters in various groups after 10 days (5 injection days, 2 days recovery, followed by 5 more days of injections) of soman exposure.

| Groups | Moment Arm | % DNA in tail | Tail length |
|---------------|------------------|-----------------|------------------|
| Control | 11.95 ± 0.83 | 1.26 ± 0.1 | 28.02 ± 1.9 |
| $0.1 LD_{50}$ | 18.18 ± 0.43 | 3.48 ± 0.35 | 45.03 ± 1.12 |
| $0.2 LD_{50}$ | 21.04 ± 1.26 | 3.00 ± 0.37 | 49.76 ± 2.74 |
| $0.4 LD_{50}$ | 22.38 ± 1.39 | 3.96 ± 0.41 | 53.08 ± 3.16 |

Table 2 shows the average comet measures for animals tested on day 29 (5 days exposure, 2 days recovery, 5 more days of exposure, followed by 17 days recovery). All measures of DNA damage were significantly elevated in all experimental groups for all doses studied. The average comet moment arm increased from 8.02 ± 0.62 in the control group to 13.14 ± 0.60 in the $0.1LD_{50}$ group, to 13.97 ± 0.54 in the $0.2LD_{50}$ group, to 15.54 ± 0.54 in the $0.4LD_{50}$ group. The average percentage of DNA fragmentation increased from 1.38 ± 0.14 in the control group to 2.65 ± 0.22 in the $0.1LD_{50}$ group, to 2.68 ± 0.19 in the $0.2LD_{50}$ group, to 3.30 ± 0.27 in the $0.4LD_{50}$ group. The average comet tail length increased from 20.48 ± 1.45 in the control group, to 35.03 ± 1.72 in the $0.1LD_{50}$ group, to 37.42 ± 1.64 in the $0.2LD_{50}$ group, to 41.80 ± 1.61 in the $0.4LD_{50}$ group.

Table 2: Comet parameters in various groups after 29 days (5 injection days, 2 days recovery, 5 more days of injections, followed by 17 days recovery) of soman exposure.

| Groups | Moment Arm | % DNA in tail | Tail length |
|---------------|------------------|-----------------|------------------|
| Control | 8.02 ± 0.62 | 1.38 ± 0.14 | 20.48 ± 1.45 |
| $0.1 LD_{50}$ | 13.14 ± 0.6 | 2.65 ± 0.22 | 35.03 ± 1.72 |
| $0.2 LD_{50}$ | 13.97 ± 0.54 | 2.68 ± 0.19 | 37.42 ± 1.68 |
| $0.4 LD_{50}$ | 15.54 ± 0.54 | 3.30 ± 0.27 | 41.8 ± 1.61 |

Table 3 shows the average comet measures for animals tested on day 122 (5 days exposure, 2 days recovery, 5 more days of exposure, followed by 110 days recovery). All measures of DNA damage were returned control levels and no significant changes were observed in all experimental groups for all doses studied. The average comet moment arm increased from 8.02 ± 0.62 in the control group to 13.14 ± 0.60 in the $0.1LD_{50}$ group, to 13.97 ± 0.54 in the $0.2LD_{50}$ group, to 15.54 ± 0.54 in the $0.4LD_{50}$ group. The average percentage of DNA fragmentation increased from 1.38 ± 0.14 in the control group to 2.65 ± 0.22 in the $0.1LD_{50}$ group, to 2.68 ± 0.19 in the $0.2LD_{50}$ group, to 3.30 ± 0.27 in the $0.4LD_{50}$ group. The average comet tail length increased from 20.48 ± 1.45 in the control group, to 35.03 ± 1.72 in the $0.1LD_{50}$ group, to 37.42 ± 1.64 in the $0.2LD_{50}$ group, to 41.80 ± 1.61 in the $0.4LD_{50}$ group.

Table 3: Comet parameters in various groups after 122 days (5 injection days, 2 days recovery, 5 more days of injections, followed by 110 days recovery) of soman exposure.

| Groups | Moment Arm | % DNA in tail | Tail length |
|---------------|------------------|-----------------|------------------|
| Control | 10.65 ± 0.54 | 4.40 ± 0.21 | 25.42 ± 0.52 |
| $0.1 LD_{50}$ | 11.58 ± 0.69 | 4.70 ± 0.18 | 26.74 ± 0.51 |
| $0.2 LD_{50}$ | 11.52 ± 0.59 | 4.41 ± 0.12 | 25.72 ± 0.37 |
| $0.4 LD_{50}$ | 11.23 ± 0.68 | 4.72 ± 0.16 | 25.91 ± 0.47 |

Discussion

The results of the present study suggest that comet assays, or other measures of apoptosis or DNA damage in blood leukocytes, may provide sensitive biomarkers for assessment of cellular damage associated with low dose CWNA exposure. Indeed, in the present study, increased DNA fragmentation could be detected in blood leukocytes over two weeks after exposure to even the lowest dose of soman used in this study, which did not elicit overt pathology.

Organophosphates such as soman and sarin exert their toxic effects primarily through a potent inhibitory action on acetylcholinesterase, the enzyme that degrades the neurotransmitter acetylcholine. This leads to increased concentrations of acetylcholine in the brain and at neuromuscular junctions, resulting in epileptic seizures and muscle tetany. Soman (methylphosphonofluoridic acid 1,2,2-trimethylpropyl ester) is a potent acetylcholinesterase inhibitor [1]. The neuropathological sequelae of severe soman toxicity include neural lesions of the amygdala, hippocampus, piriform cortex, and thalamus [6]. However, the effects of organophosphate poisoning on the immune system have been less well characterized.

Sub-lethal doses of soman resulted in significant increases in all measures of leukocyte DNA fragmentation, at all doses and time points examined, as compared with saline-injected control animals. While these results demonstrate moderately increased leukocyte apoptosis following low dose soman exposure, the mechanism by which apoptosis is elicited is unknown. Similarly, the pathological and/or immune consequences of small, but statistically significant increases in leukocyte apoptosis following soman-exposure are unknown. No clear dose-response effect on DNA fragmentation was observed using the comet method, but direct cell counts demonstrated a dose-response relationship to the percentage of apoptotic cells. This finding is certainly

not indicative of poor usefulness of the comet assay, but suggests that among the affected leukocytes in each experimental condition the degree of DNA damage was not different, however, the percentage of affected leukocytes was directly related to the dose of soman. An unexpected finding in the present study was the long-term nature of the DNA damage associated with low-level soman exposure. Significantly, increased measures of apoptosis were observed after 17 days of recovery after the last exposure to the toxicant. Long-term reductions in leukocyte responsiveness have been reported after low-level exposure to another CWNA, sarin [7], but the mechanism by which such long term leukocytic damage occurs is not known. Considering the long term nature of the damage, it is possible that organophosphates cause damage at the level of stem cells in the bone marrow, which could then lead to increased apoptosis in the derived leukocytes.

While the link between organophosphate poisoning and leukocyte apoptosis remains uncertain, data suggest that reactive oxygen molecules may be involved in neuronal apoptosis after exposure to the cholinesterase inhibitor pyridostigmine bromide [8]. It was found that the release of reactive oxygen species after pyridostigmine bromide treatment was mediated by muscarinic acetylcholine receptors, and NMDA glutamate receptors, and that pretreatment with atropine or MK-801 blocked reactive oxygen species generation. It is possible that similar mechanisms could be involved in the leukocyte damage observed in the present study after soman exposure. If confirmed in the case of nerve agent exposure, current organophosphate poisoning treatments may benefit by cotreatment with antioxidant compounds, and inhibitors of reactive oxygen species generation.

References

- [1] US Army Field Manual 3-9, US Navy Publication P-467, US Air Force Manual 355-7 (1990), 'Potential Military Chemical/Biological Agents and Compounds', **21**: Table 2-4.
- [2] Persian Gulf War Veterans Coordinating Board (1995), Unexplained illness among Desert Storm Veterans. *Arch Intern Med.*, **155**: 262-268.
- [3] Lim, D.K., Hoskins, B., Ho, I.K. (1991) Trihexylphenidyl enhances physostigmine prophylaxis against soman poisoning in guinea pigs. *Fund Appl Toxicol.*, **16**: 482-489.
- [4] McDonough JH and Shih T-M (1993) Pharmacological modulation of soman-induced seizures. *Neurosci Behav Rev.*, **17**: 203-215.
- [5] Raveh L, Chapman S, Cohen G, Alkalay D, Gilat E, Rabinovitz I, Weissman BA (1999) The involvement of the NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning. *NeuroToxicol.*, **20**: 551-559.
- [6] de Groot, DM, Bierman, EP, Bruijnzeel, PL, Carpentier, P, Kulig, BM, Lallement, G, Melchers, BP, Philippens, IH, van Huygevoort, AH. (2001) Beneficial effects of TCP on soman intoxication in guinea pigs: seizures, brain damage and learning behaviour. *J Appl Toxicol. Suppl*, Dec 21, **1**: S57-65.
- [7] Kassa, J., Krocova, Z., and Vachek, J (2000) Long term alteration of immune functions following low level exposure to sarin in rats. *Acta Medica*, **43**: 91-94.
- [8] Li, L, Shou, Y, Borowitz, JL, Isom, GE (2001) Reactive oxygen species mediate pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and NMDA receptors. *Toxicol Appl Pharmacol.*, **177**: 17-25.

FOOTNOTE

Research was conducted in compliance with the Animal Welfare Act, and other Federal statutes and regulation relating to animals and experiments involving animals and adheres to the principles stated in the Guide for the Care and Use of Laboratory Animals, NIH publication 85-23. The views of the authors do not purport to reflect the position of the Department of the Army or the Department of Defense, (para 4-3), AR 360-5. Part of these data has been published earlier (Moffett *et al*, *Cellular and Molecular Life Sciences*, **60**: 2266-2271, 2003).